Immunotherapy of Minimal Residual Disease by Immunocompetent Lymphocytes and Their Activation by Cytokines

References

• Slavin S, Eckerstien A, Morecki S, Weiss L. Hypothesis: The mechanisms of the GVL phenomenon in clinical BMT. Bone Marrow Transplant 1990; 6: 155–161
   PubMed Web of Science ®Google Scholar
• Bolhuis R LH, Gravekamp C, Van de Griend R J. Cell-cell interactions. Clin Immunol Allergy 1986; 6: 29
   Google Scholar
• Lanier L L, Phillips J H. What are natural killer cells. ISl Atlas of Science Immunology. 1988; 15–19
   Google Scholar
• Brenner M B, McLean J, Dialynas D P. Identification of a putative second T-cell receptor. Nature (London) 1986; 322: 145
   PubMed Web of Science ®Google Scholar
• Borst J J, Van de Griend J, Van Oostveen W. A T-cell receptor TCT/CD3 complex found on cloned functional lymphocytes. Nature 1987; 325: 683
   PubMed Web of Science ®Google Scholar
• LeFever A V, Truitt R L, Shih C-Y. Reactivity of in-vitro-expanded alloimmune cytotoxic T lymphocytes and Qa-1-specific cytotoxic T lymphocytes against AKR leukemia in vivo. Transplantation 1985; 40: 531–537
   PubMed Web of Science ®Google Scholar
• Truitt R L, Shih C-Y, LeFever A V. Characterization of alloimmunization-induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft-versus-leukemia activity in vivo. J Immunol 1983; 131: 2050
   PubMed Web of Science ®Google Scholar
• Topalian S L, Solomon D, Avis F P. Immunotherapy of patients with advanced cancer using tumor infiltrating lymphocytes and recombinant IL2: a pilot study. J Clin Oncol 1988; 6: 839–853
   PubMed Web of Science ®Google Scholar
• Weiden P L, Fluornoy N, Thomas E D. Antileukemic effects of graft versus host disease in human recipients of allogeneic marrow grafts. N Engl J Med 1979; 300: 1068
   PubMed Web of Science ®Google Scholar
• Sullivan K M, Fefer A, Witherspoon R. Graft-versus-leukemia in man: relationship of acute and chronic graft-versus-host disease to relapse of acute leukemia following allogeneic bone marrow transplantation. Cell Immunotherapy of Cancer. Alan R Liss, New York 1987; 391–399
   Google Scholar
• Ringden O, Horowitz M M. Graft-vs-leukemia reactions in humans. Transplant Proc 1989; 21: 2989–2992
   PubMed Web of Science ®Google Scholar
• Horowitz M M, Gale R P, Sondel P M. Graft versus leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562
   PubMed Web of Science ®Google Scholar
• Slavin S, Strober S. Spontaneous murine B-cell leukemia. Nature 1978; 272: 624–626
   PubMed Web of Science ®Google Scholar
• Slavin S, Weiss L, Morecki S. B-cell leukemia (BCL1), a murine model of chronic lymphocytic leukemia. 1. Ultrastructural, cell membrane and cytogenetic characteristics. Cancer Res 1981; 41: 4162–4166
   PubMed Web of Science ®Google Scholar
• Slavin S, Eckerstein A, Weiss L. Adoptive immunotherapy in conjunction with bone marrow transplantation–amplification of natural host defence mechanisms against cancer by recombinant IL2. Nat Immun Cell Growth Reg 1988; 7: 180–184
   PubMedGoogle Scholar
• Vourka U, Slavin S. Manuscript in preparation
   Google Scholar
• Slavin S, Weiss L, Morecki S, Weigensberg M. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol Immunother 1981; 11: 155–158
   Web of Science ®Google Scholar
• Weiss L, Morecki S, Vitetta E S, Slavin S. Suppression and elimination of BCL1 leukemia by allogeneic bone marrow transplantation. J Immunol 1983; 130: 2452–2455
   PubMed Web of Science ®Google Scholar
• Lui C-M, Okayasu T, Goldman P. Immune regulation of the L5178Y murine tumor-dormant state: I. In vivo and in vitro effects of prostaglandin E and indomethacin on tumor cell growth. J Exp Med 1986; 164: 1259–1273
   PubMed Web of Science ®Google Scholar
• Ackerstein A, Kedar E, Slavin S. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. II. IL2-mediated control of murine leukemia in conjunction with syngeneic bone marrow transplantation. Blood 1991; 78: 1212–1215
   PubMed Web of Science ®Google Scholar
• Shalit M, Ayalon M, Weiss L. Bone marrow transplantation with T cell depleted grafts. 1. Reconstitution of immunohemopoietic functions in lethally irradiated mice transplanted with unseparated or T-cell depleted syngeneic bone marrow grafts. Transplantation 1986; 42: 118
   PubMed Web of Science ®Google Scholar
• Weiss L, Reich S, Savin S. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. I Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL2-activated cell-medidated immunotherapy. Cancer Invest, in press
   Web of Science ®Google Scholar
• Nagler A, Ackerstein A, Naparstek E. Ambulatory cytokine-mediated immunotherapy by recombinant alpha interferon (IFNα) and interleukin-2 (IL2). 32nd Annual Meeting American Society Hematology, Boston, November, 1990
   Google Scholar
• Slavin S, Ackerstein A, Nagler A. Cell-mediated cytokine-activated immunotherapy (CCI) of malignant hematological disorders for eradication of minimal residual disease (MRD) in conjunction with conventional chemotherapy or bone marrow transplantation (BMT). 32nd Annual Meeting American Society Hematology, Boston, November, 1990
   Google Scholar
• Waldmann H, Rriliack A, Hale G. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (Campath-1). Lancet 1984; 2: 483–485
   PubMed Web of Science ®Google Scholar